The Combination of Aromatase Inhibitors and GH Treatment for Idiopathic Short Stature in Male Adolescents
An erratum to this article was published (J Clin Endocrinol Metab, 7 Aug 2025 ↗)
Authors' conclusion
For adolescent males with ISS and a bone age ≥ 13 years, the combination of AI and rhGH significantly increased the AHt. Finally, our analyses showed that anastrozole exerts more significant effects with regard to augmenting AHt with fewer adverse reactions.
Study context
- Population
- Adolescent boys with idiopathic short stature and bone age ≥ 13 years, Tongji Hospital, May 2017 to June 2023matched cohort
- Participants
- 32 / 32 / 32
- Exposure
- Letrozole + recombinant human GH (rhGH) vs anastrozole + rhGH vs GnRH analog (GnRHa) + rhGH
- Letrozolen = 32
- Anastrozolen = 32
- GnRHan = 32reference
- Outcome
- Adult height (AHt) SD score adjusted for target height
- Follow-up
- AHt
Methodological detailspropensity-score matched, single-centre, Follow-up every 3 months until adult height (AHt); adverse events monitored throughout
- Propensity-score matched
- Single-centre
- Follow-up every 3 months until AHt; adverse events monitored throughout
Main finding
As reported in the abstract
AHt SD score adjusted for target height
Letrozole
0.60
± 0.28
Anastrozole
0.81
± 0.34
GnRHa
0.48
± 0.17
P < 0.01
Observational data: associations, not effects.
Safety
- Abnormal monitoring indicators in the AI groups gradually returned to normal after treatment termination
Original publication
The Combination of Aromatase Inhibitors and GH Treatment for Idiopathic Short Stature in Male Adolescents. J Clin Endocrinol Metab. Published 6 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →